CD8A and neoplasm: In addition, accumulating data supports the notion that baseline tumor infiltration by activated CD8+ T cells (inflamed tumors) identifies a group of patients with a better chance for a clinical response to treatment with immunotherapy when compared to patients with non-inflamed tumors [9,10].